For patients with T2D, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and CV event risks.

Women with immune-mediated inflammatory diseases (IMIDs) face higher CVD-related mortality rates than do men, according to recently published research.

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 ...

A heart attack survivor has been reunited with the ambulance crew who saved his life, just weeks after their intervention ...

Finally, June 24, Gyu Seong Heo from the Department of Radiology, Washington University, will present ‘Preclinical assessment of 64Cu-LNTH-1363S for FAP PET imaging in mouse models of myocardial ...

A heart attack survivor has been reunited with the ambulance crew who saved his life, just weeks after their intervention ...

LOS ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today announced the appointment of Dr. Peter Libby, ...

A US-based doctor has shared three signs of a heart attack that everyone must know, including a less common symptom that ...

Heart attack and stroke make for 85% of the total deaths caused due to cardiovascular diseases. Heart attack can happen due ...

While low-density lipoprotein cholesterol (LDL-C) management is a central pillar of CVD treatment, many patients continue to ...

Digital tool equips healthcare providers with trusted visual content to simplify complex heart information at the point of care LEXINGTON, Ky., June 23, 2025 /PRNewswire/ -- Medmovie, Inc., a leader ...

Meril Life Sciences unveils MyClip, a groundbreaking Transcatheter Edge-to-Edge Repair system for treating severe Mitral ...